<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="703315659476 doi: 10.1038/s41598-020-59476-4 : Article An electronic alert system increases" exact="screening" post="for hepatitis B and C and improves management of"/>
 <result pre="haematological disorders in patients with chronic hepatitis B or resolved" exact="infection" post="(anti-HBc-positive) is associated with a risk of hepatitis B"/>
 <result pre="general population. An electronic alert system was developed to promote" exact="screening" post="of hepatitis B (HBV) and C (HCV) in patients"/>
 <result pre="C (HCV) in patients starting haematological therapies. The system included" exact="screening" post="and linkage to care and a request for testing"/>
 <result pre="included screening and linkage to care and a request for" exact="testing" post="in those without data. From March, 2017 to March,"/>
 <result pre="At first prescription before the alerts, the HCV and HBV" exact="screening" post="rate was 60.5%. Following the alerts, an additional 115"/>
 <result pre="the alerts, an additional 115 were screened, increasing the overall" exact="screening" post="rate to 87.9%. Anti-HBc alone was detected in 57,"/>
 <result pre="not know, and the impact was particularly important for anti-HBc" exact="detection" post="(47/57 unknown). Nucleoside analogues were prescribed in 28 (49.1%)"/>
 <result pre="2 HBsAg-positive patients. Prospective follow-up with HBV DNA and HBsAg" exact="testing" post="showed no cases of HBV reactivation. An estimated 1.2"/>
 <result pre="system. In summary, an electronic alert system increased viral hepatitis" exact="screening" post="in patients receiving haematological treatment and led to improvements"/>
 <result pre="alert system increased viral hepatitis screening in patients receiving haematological" exact="treatment" post="and led to improvements in the management of these"/>
 <result pre="Funding https://doi.org/10.13039/100005564Gilead Sciences (Gilead) GoSHAPE European programme grantRiveiro-BarcielaMar Introduction Viral" exact="infection" post="by hepatitis B and C plays an important role"/>
 <result pre="virus (HBV) infection, (i.e., HBsAg-positive), and even those with resolved" exact="infection" post="(HBsAg-negative/anti-HBc-positive) are at risk of HBV reactivation when receiving"/>
 <result pre="especially those treated with rituximab-containing regimens2. The importance of HBV" exact="screening" post="lies in the potential severity of HBV reactivation, ranging"/>
 <result pre="who will benefit from HBV prophylaxis5. However, the rate of" exact="testing" post="for viral hepatitis in the haematological population is relatively"/>
 <result pre="in the haematological population is relatively low. The reported HBV" exact="screening" post="rate in patients with haematological malignancies in a large"/>
 <result pre="the possibility of HBV reactivation. In one study, the HBsAg" exact="screening" post="rate rose from 47% to 94% and anti-HBc screening"/>
 <result pre="HBsAg screening rate rose from 47% to 94% and anti-HBc" exact="screening" post="from 30% to 85%7. As to hepatitis C virus"/>
 <result pre="the most commonly linked malignancies9. In view of the high" exact="prevalence" post="of HCV in haematological patients and the potential risk"/>
 <result pre="we developed an electronic alert system (EAS) to increase the" exact="screening" post="rate in patients with haematological malignancies undergoing specific therapy."/>
 <result pre="which facilitates referral of individuals with positive serology and requests" exact="testing" post="in patients without this information. The aim of this"/>
 <result pre="of its implementation on the rate of HBV and HCV" exact="screening" post="in patients with haematological malignancies undergoing specific therapies. In"/>
 <result pre="Performance of the electronic alert system Impact on viral hepatitis" exact="screening" post="At the first prescription, the serological panel was completed"/>
 <result pre="the serological panel was completed in 254 (60.5%) patients. The" exact="screening" post="rate clearly differed according to the type of treatment."/>
 <result pre="66%, p &amp;lt; 0.001). The haematological malignancy also had an impact on" exact="screening" post="(p &amp;lt; 0.001), with the highest percentage of completed panels seen"/>
 <result pre="additional cases were tested for viral hepatitis, increasing the overall" exact="screening" post="rate to 87.9% (Fig. 1). Percentage of completed panel"/>
 <result pre="rate to 87.9% (Fig. 1). Percentage of completed panel of" exact="screening" post="according to the epidemiological, clinical, and therapeutic factors of"/>
 <result pre="regimens and DLBCL patients were the ones with the highest" exact="screening" post="rates, whereas those receiving tyrosine-kinase inhibitors or and patients"/>
 <result pre="Figure 1 Impact of the electronic alert system (EAS) on" exact="screening" post="for viral hepatitis markers. At the start of new"/>
 <result pre="the total. Following the alerts provided by the EAS, the" exact="screening" post="rate significantly increased to 87.9%. Table 2 Overall viral"/>
 <result pre="rate significantly increased to 87.9%. Table 2 Overall viral hepatitis" exact="screening" post="rate according to epidemiological, clinical and therapeutic factors. Factor"/>
 <result pre="0.003 Tyrosine-kinase inhibitors 64 62.5% &amp;lt;0.001 *Comparison of rate of" exact="screening" post="in contrast with the rest of the cohort. Prevalence"/>
 <result pre="EAS (Fig. 1). Therefore, the status of 68% of patients" exact="testing" post="positive for viral hepatitis markers had been unknown previously."/>
 <result pre="viral hepatitis markers had been unknown previously. Management of patients" exact="testing" post="positive for HBV markers Despite the EAS recommendations (Fig."/>
 <result pre="2 Flow chart showing the electronic alert system (EAS) for" exact="screening" post="of viral hepatitis markers in patients undergoing haematological therapy."/>
 <result pre="the prescription application was created to remind physicians and facilitate" exact="testing" post="for HBsAg, anti-HBc, and anti-HCV in haematological patients. In"/>
 <result pre="vs 292, respectively, p = 0.232). The two HBsAg-positive patients received antiviral" exact="treatment" post="and achieved virological suppression (undetectable HBV DNA), which was"/>
 <result pre="the estimated risk of HBV reactivation in anti-HBc-positive patients receiving" exact="treatment" post="for hematological malignancies is 2.4% in those with antiviral"/>
 <result pre="alert system had a positive impact on the viral hepatitis" exact="screening" post="rate in haematological patients receiving specific therapies, with an"/>
 <result pre="of patients. The importance of the EAS lies in the" exact="diagnosis" post="of previously unknown viral hepatitis markers, particularly HBV. In"/>
 <result pre="of chronic hepatitis C, which led to the start of" exact="treatment" post="with direct-acting antiviral agents and sustained virological response. Currently,"/>
 <result pre="response. Currently, considerable effort worldwide is devoted to promoting HCV" exact="screening" post="programs (including microelimination programs in targeted populations) to achieve"/>
 <result pre="disease and therapy scheme, but mainly on HBV status2,14. Hence," exact="testing" post="for viral hepatitis markers before starting these drugs is"/>
 <result pre="the use of alert systems has been explored to improve" exact="screening" post="rates7,12. Sampedro et al. reported that use of a"/>
 <result pre="system for patients treated with biologic agents led to a" exact="screening" post="rate for HBV markers greater than 85%7, a value"/>
 <result pre="than 85%7, a value comparable to the overall percentage of" exact="testing" post="in our cohort after the EAS alerts. Another important"/>
 <result pre="reactivation16,17. In our cohort, the malignancy associated with the lowest" exact="screening" post="rate was CML. The risk of HBV reactivation associated"/>
 <result pre="left to the discretion of the treating haematologist in patients" exact="testing" post="positive only for anti-HBc. This design also provided interesting"/>
 <result pre="of antiviral prophylaxis25. In our cohort, although the concern for" exact="screening" post="was low in the population receiving tyrosine kinase inhibitors"/>
 <result pre="in the population receiving tyrosine kinase inhibitors (62.5%), the complete" exact="testing" post="data showed 17 anti-HBc-positive individuals. Among these, 12 (70.6%)"/>
 <result pre="of reactivation during the first year of therapy. Regarding the" exact="prevalence" post="of viral hepatitis, 3.2% of patients tested anti-HCV positive,"/>
 <result pre="had already achieved sustained virological response. As was expected, the" exact="prevalence" post="of HBsAg and anti-HBc was similar to previously reported"/>
 <result pre="alert system had a positive impact on the viral hepatitis" exact="screening" post="rate in patients receiving haematological therapy. This, in turn,"/>
 <result pre="to an improvement in the management of these patients, with" exact="diagnosis" post="of previously unknown cases of chronic viral hepatitis and"/>
 <result pre="to remind physicians of the need for HBV and HCV" exact="testing" post="in certain patients. The EAS was linked to the"/>
 <result pre="according to the scheme summarized in Fig. 2. In patients" exact="testing" post="HBsAg or antiHBc positive and those with unknown status,"/>
 <result pre="the physicians’ work and achieve relevant data, 3 preconfigured blood" exact="tests" post="were created: one to complete the study of HBsAg-positive"/>
 <result pre="biochemistry, clotting, HIV serology, and HCV genotype). Whenever a new" exact="treatment" post="schedule was prescribed, the computerized system requested the patient’s"/>
 <result pre="been previously introduced. If data were lacking and viral hepatitis" exact="screening" post="had not been performed within the first 3 months"/>
 <result pre="at the first prescription were checked for later viral hepatitis" exact="screening" post="requests from the Haematology Department. Number of patients with"/>
 <result pre="Helsinki, Good Clinical Practice guidelines, and local regulatory requirements. Since" exact="screening" post="of viral hepatitis markers is considered within recommended daily"/>
 <result pre="HBsAg-negative/anti-HBc-positive (reverse seroconversion)28. Patient selection All haematological patients receiving specific" exact="treatment" post="(including monoclonal antibodies in monotherapy) from 1 March, 2017,"/>
 <result pre="all cases, epidemiological (race, date of birth, sex), clinical (malignancy," exact="treatment" post="regimen, previously known viral hepatitis infection, prior treatment for"/>
 <result pre="clinical (malignancy, treatment regimen, previously known viral hepatitis infection, prior" exact="treatment" post="for viral hepatitis, antiviral therapy), and serological (HBsAg, anti-HBc,"/>
 <result pre="HIV if available) data were recorded, as well as antiviral" exact="treatment" post="for chronic hepatitis C and nucleos(t)ide analogue prophylaxis for"/>
 <result pre="to immunosuppressive drug treatmentsJama20153131617161810.1001/jama.2015.257125790287 6.HwangJPet al.Trends in hepatitis B virus" exact="screening" post="at the onset of chemotherapy in a large US"/>
 <result pre="surface antibody in hepatitis B reactivation in patients with resolved" exact="infection" post="and hematologic malignancy: A meta-analysisHepatology (Baltimore, Md.)20176637938810.1002/hep.29082 11.HuangYHet al.Randomized"/>
 <result pre="journal2017763110.1038/s41408-017-0002-229167420 18.PerrilloRPGishRFalck-YtterYTAmerican Gastroenterological Association Institute technical review on prevention and" exact="treatment" post="of hepatitis B virus reactivation during immunosuppressive drug therapyGastroenterology2015148221244.e22310.1053/j.gastro.2014.10.03825447852"/>
 <result pre="myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during" exact="treatment" post="with imatinib rescued by liver transplantation: case report and"/>
 <result pre="and literature reviewInternational journal of hematology20099038338710.1007/s12185-009-0386-219641858 23.AndoTet al.Reactivation of resolved" exact="infection" post="with the hepatitis B virus immune escape mutant G145R"/>
 <result pre="the hepatitis B virus immune escape mutant G145R during dasatinib" exact="treatment" post="for chronic myeloid leukemiaInternational journal of hematology201510237938210.1007/s12185-015-1788-y25842192 24.ThiaTJTanHHChuahTHChowWCLuiHFImatinib mesylate-related"/>
 <result pre="risk of hepatitis B virus reactivation in patients with resolved" exact="infection" post="and chronic myeloid leukemia treated with tyrosine kinase inhibitorsLeukemia"/>
 <result pre="26.Rodríguez-Tajes, S. et al. Prevalence of Hepatitis B and C" exact="infection" post="in Catalonia. Annual meeting of the AEEH. (2017). 27.Salleras,"/>
 <result pre="meeting of the AEEH. (2017). 27.Salleras, L. et al. Declining" exact="prevalence" post="of hepatitis B virus infection in Catalonia (Spain) 12"/>
 <result pre="27.Salleras, L. et al. Declining prevalence of hepatitis B virus" exact="infection" post="in Catalonia (Spain) 12 years after the introduction of"/>
</results>
